March 25, 2022

A clinical-stage biotech company developing a targeted oral small molecule for synergistic combinations with SOC -that's Cardiff Oncology.

A clinical-stage biotech company developing a targeted oral small molecule for synergistic combinations with SOC -that's Cardiff Oncology.

Everyone is excited about KRAS, the “undruggable” target that now has a drug. However, that drug only hits one specific, rather rare KRAS mutation, leaving the vast majority of patients with KRAS mutant variants who, after exhausting standard of care (SOC), are left without any effective treatment options. So, what if you had a drug that hit just downstream in the KRAS pathway, and further, was synergistic with SOC – wouldn’t that serve all such patients? Yes. Yes, it would. That drug is called Onvansertib, from Cardiff Oncology.